140 related articles for article (PubMed ID: 38336778)
1. Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.
Kosumi T; Kobayashi M; Shimodaira S; Sugiyama H; Koido S
J Med Case Rep; 2024 Feb; 18(1):88. PubMed ID: 38336778
[TBL] [Abstract][Full Text] [Related]
2. Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
Wu K; Guo C; Li R
Medicine (Baltimore); 2019 May; 98(18):e15489. PubMed ID: 31045832
[TBL] [Abstract][Full Text] [Related]
3. Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial.
Nagai K; Adachi T; Harada H; Eguchi S; Sugiyama H; Miyazaki Y
Anticancer Res; 2020 Oct; 40(10):5765-5776. PubMed ID: 32988904
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Drpa G; Sreter KB; Manojlovic S; Kukulj S
Anticancer Drugs; 2018 Mar; 29(3):281-285. PubMed ID: 29280916
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
Markóczy Z; Sárosi V; Kudaba I; Gálffy G; Turay ÜY; Demirkazik A; Purkalne G; Somfay A; Pápai-Székely Z; Rásó E; Ostoros G
BMC Cancer; 2018 May; 18(1):598. PubMed ID: 29801465
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report.
Šťastná N; Jakubíková L; Brat K
Klin Onkol; 2020; 33(3):226-229. PubMed ID: 32683880
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
9. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models.
Venugopalan A; Lee MJ; Niu G; Medina-Echeverz J; Tomita Y; Lizak MJ; Cultraro CM; Simpson RM; Chen X; Trepel JB; Guha U
Oncotarget; 2016 Aug; 7(34):54137-54156. PubMed ID: 27494838
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
11. T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.
Kusaba Y; Takeda Y; Abe S; Tsukada A; Naka G
Medicine (Baltimore); 2022 Aug; 101(32):e29682. PubMed ID: 35960133
[TBL] [Abstract][Full Text] [Related]
12. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
Wang M; Zhu F; Luo N; Li M; Qi Y; Wang M
Medicine (Baltimore); 2021 Nov; 100(44):e27727. PubMed ID: 34871271
[TBL] [Abstract][Full Text] [Related]
14. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
Sari M; Aydiner A
J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib and Trametinib in Patients With
Luo J; Makhnin A; Tobi Y; Ahn L; Hayes SA; Iqbal A; Ng K; Arcila ME; Riely GJ; Kris MG; Yu HA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250388
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.
Yokoyama A; Tamura A; Miyakawa K; Kusaka K; Shimada M; Hirose T; Matsui H; Kitani M; Hebisawa A; Ohta K
Intern Med; 2018 Aug; 57(16):2377-2382. PubMed ID: 29526950
[TBL] [Abstract][Full Text] [Related]
18. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Lu RL; Hu CP; Yang HP; Li YY; Gu QH; Wu L
Pathol Oncol Res; 2014 Apr; 20(2):445-51. PubMed ID: 24297623
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment.
Yen YC; Hsu HL; Chang JH; Lin WC; Chang YC; Chang CL; Chow JM; Yuan KS; Wu ATH; Wu SY
Radiother Oncol; 2018 Oct; 129(1):52-60. PubMed ID: 29703499
[TBL] [Abstract][Full Text] [Related]
20. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]